Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | HTR4 | Q13639 | 15/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6770784 | 0.99 | KCNH2 (0.59) | KCNH2HTR4HTR3ACYP3A4CYP2D6 | |
| SCHEMBL6767167 | 0.92 | KCNH2 (0.62) | KCNH2HTR4HTR3A | |
| SCHEMBL6177604 | 0.90 | KCNH2 (0.74) | KCNH2HTR4HTR3ACYP3A4CYP2D6 | |
| SCHEMBL6765012 | 0.88 | HTR4 (0.57) | KCNH2HTR4HTR3A | |
| SCHEMBL5889439 | 0.87 | KCNH2 (0.61) | KCNH2HTR4HTR3A | |
| SCHEMBL8345408 | 0.87 | KCNH2 (0.68) | KCNH2HTR4HTR3A | |
| SCHEMBL6179088 | 0.87 | KCNH2 (0.62) | KCNH2HTR4HTR3A | |
| SCHEMBL5889424 | 0.86 | KCNH2 (0.59) | KCNH2HTR4HTR3A | |
| SCHEMBL6177156 | 0.85 | HTR4 (0.59) | KCNH2HTR4CYP3A4CYP2D6 | |
| SCHEMBL5889899 | 0.85 | KCNH2 (0.62) | KCNH2HTR4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440071-B1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | PFIZER (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | KCNH2 962/4885HTR4 1/4885HTR3A 28/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | KCNH2 895/4885HTR4 2/4885HTR3A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.